Company intelligence / Profile preview

Neurizon Therapeutics

South Melbourne, Victoria, Australianeurizon.com ↗

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Neurizon Therapeutics’ lead candidate NUZ‑001 has shown positive safety and tolerability in a completed Phase I trial in ALS patients. The drug is entering a regimen-specific arm of the HEALEY ALS Platform Trial at Massachusetts General Hospital for a pivotal Phase II/III study starting in 2025. Preclinical studies have demonstrated significant blood–brain barrier penetration and neuroprotective effects across multiple neurodegenerative models. The company holds Orphan Drug Designation from both the FDA and EMA for ALS.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

NUZ-001 sulfone

Unknown

Partnerships

Syngene International Ltd.Catalent Inc.Massachusetts General Hospital / HEALEY ALS Platform Trial

Beyond the preview

Go deeper on Neurizon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurizon Therapeutics.

Explore the full profile